Your browser doesn't support javascript.
loading
An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
Han, Guangchun; Sinjab, Ansam; Rahal, Zahraa; Lynch, Anne M; Treekitkarnmongkol, Warapen; Liu, Yuejiang; Serrano, Alejandra G; Feng, Jiping; Liang, Ke; Khan, Khaja; Lu, Wei; Hernandez, Sharia D; Liu, Yunhe; Cao, Xuanye; Dai, Enyu; Pei, Guangsheng; Hu, Jian; Abaya, Camille; Gomez-Bolanos, Lorena I; Peng, Fuduan; Chen, Minyue; Parra, Edwin R; Cascone, Tina; Sepesi, Boris; Moghaddam, Seyed Javad; Scheet, Paul; Negrao, Marcelo V; Heymach, John V; Li, Mingyao; Dubinett, Steven M; Stevenson, Christopher S; Spira, Avrum E; Fujimoto, Junya; Solis, Luisa M; Wistuba, Ignacio I; Chen, Jichao; Wang, Linghua; Kadara, Humam.
Afiliación
  • Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sinjab A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rahal Z; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lynch AM; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Treekitkarnmongkol W; Graduate Program in Developmental Biology, Baylor College of Medicine, Houston, TX, USA.
  • Liu Y; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Serrano AG; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng J; The University of Texas Health Houston Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Liang K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Khan K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lu W; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hernandez SD; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu Y; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cao X; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dai E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pei G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hu J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Abaya C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gomez-Bolanos LI; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Peng F; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen M; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Parra ER; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cascone T; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sepesi B; The University of Texas Health Houston Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Moghaddam SJ; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Scheet P; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Negrao MV; Department of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Heymach JV; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Li M; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dubinett SM; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stevenson CS; Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Spira AE; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Fujimoto J; Department of Medicine, The University of California Los Angeles, Los Angeles, CA, USA.
  • Solis LM; Lung Cancer Initiative at Johnson & Johnson, Boston, MA, USA.
  • Wistuba II; Lung Cancer Initiative at Johnson & Johnson, Boston, MA, USA.
  • Chen J; Section of Computational Biomedicine, School of Medicine, Boston University, Boston, MA, USA.
  • Wang L; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kadara H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nature ; 627(8004): 656-663, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38418883
ABSTRACT
Understanding the cellular processes that underlie early lung adenocarcinoma (LUAD) development is needed to devise intervention strategies1. Here we studied 246,102 single epithelial cells from 16 early-stage LUADs and 47 matched normal lung samples. Epithelial cells comprised diverse normal and cancer cell states, and diversity among cancer cells was strongly linked to LUAD-specific oncogenic drivers. KRAS mutant cancer cells showed distinct transcriptional features, reduced differentiation and low levels of aneuploidy. Non-malignant areas surrounding human LUAD samples were enriched with alveolar intermediate cells that displayed elevated KRT8 expression (termed KRT8+ alveolar intermediate cells (KACs) here), reduced differentiation, increased plasticity and driver KRAS mutations. Expression profiles of KACs were enriched in lung precancer cells and in LUAD cells and signified poor survival. In mice exposed to tobacco carcinogen, KACs emerged before lung tumours and persisted for months after cessation of carcinogen exposure. Moreover, they acquired Kras mutations and conveyed sensitivity to targeted KRAS inhibition in KAC-enriched organoids derived from alveolar type 2 (AT2) cells. Last, lineage-labelling of AT2 cells or KRT8+ cells following carcinogen exposure showed that KACs are possible intermediates in AT2-to-tumour cell transformation. This study provides new insights into epithelial cell states at the root of LUAD development, and such states could harbour potential targets for prevention or intervention.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diferenciación Celular / Células Epiteliales / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Animals / Humans Idioma: En Revista: Nature Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diferenciación Celular / Células Epiteliales / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Animals / Humans Idioma: En Revista: Nature Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos